POST ICML Indolent lymphomas relapse treatment
|
|
- Rose Nicholson
- 5 years ago
- Views:
Transcription
1 POST ICML Indolent lymphomas relapse treatment Georg Hess University Medical School Johannes Gutenberg-University Mainz, Germany
2 Treatment of relapsed indolent lymphoma 2
3 General categories of second line approaches Standard patients re-treatment Intensive, curative approaches HDT, allogeneic SCT Novel agents moab, Pathway inhibitors, epigenetic modulation, immune modulators New combination therapies chemoimmunotherapy plus novel agents 3
4 High dose therapy 4
5 HDT for transformed indolent lymphoma Trial: NCIC CTG LY12 (8/ /2011) Patients with rel aggressive lymphoma, < 3 lines R (R)-GCP x 3 (R)-DHAP x 3 HDT 619 patients, 89 with transformed lymphoma, 428 DLBCL Approx. 70% prior R-exposure, 30% R-refractory Median follow up 53 months Transformed DLBCL Response to salvage 54% 54% Transplantation rate 52% 52% EFS (4 yr) 26% 27% OS (4 yr) 38% 41% Kuravilla-J et al, ICML 2013, Abstr. 64 5
6 Novel Antibodies 6
7 Focus on: Antibody drug conjugates - Background An ADC is a drug delivery technology where drugs are linked to an antibody via a conditionally stable linker The antibody delivers drug to target cells by binding to antigen on cell surface The drug is released in target cells upon internalisation Achieving highly specific therapy with higher toxic dosis at the specific location Local delivery of high toxic chemo-agent to achive general lower adverse reactions Generating a targeted chemotherapy in combination with subcutaneous or oral given agents Senter PD. Curr Opin Chem Biol 2009;13:
8 Anti-CD22 Antibody-Drug Conjugate (ADC): DCDT2980S Anti-CD22 monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a protease-cleavable peptide linker MMAE: potent microtubule disrupting agent CD22 is a cell-surface antigen whose expression is restricted to all mature B cells except plasma cells Expressed by nearly all B-cell hematologic malignancies Rapid internalization upon binding Potent anti-tumor activity in murine xenograft models of B-cell lymphoma mg/kg Anti-CD22vcE Genentech, Data on File Advani et al, ICML 2013, Abstr Ramos (BL) 2 mg/kg Anti-CD22vcE R-CHOP
9 Patient Baseline Characteristics Demographics (N=43 patients) All Patients n (%) Histology Patients n (%) Age in years, median (range) 66 (30-85) Diffuse large B-cell lymphoma 22 (51) Sex Female Male ECOG status No. systemic therapies, median (range) (47) 23 (53) 19 (45) 20 (48) 3 (7) 4 (1-11) 5 (12) 4 (9) 34 (79) Follicular lymphoma 15 (35) Transformed follicular lymphoma 4 (9) Small lymphocytic lymphoma 2 (5) Prior rituximab therapy 43 (100) Autologous stem cell transplant therapy 7 (16)
10 Treatment Emergent Adverse Events * Per investigator assessment
11 Investigator-Assessed Best Responses in patients with at least 1 dose Best Response Efficacy-Evaluable Patients, 1.8 mg/kg (n=17) Objective response b 7 (41%) Partial Response Complete Response Histology DLBCL FL 6 (35%) c 1 (6%) b Stable disease 4 (24%) Progressive disease 5 (29%) Unable to evaluate 1 (6%) Lugano Update on inhl (n=16) Antibody only (n=11) 3(27%) Antibody plus rituximab (n=5) 1(20%) 5 (4 PR, 1 CR b) 2 (PR) Efficacy-evaluable patients defined as those patients who received at least one dose of study treatment and had at least one on-treatment tumor assessment. Disease measured by Cheson criteria. Advani et al, ICML 2013, Abstr. 39
12 Anti-CD79b Antibody-Drug Conjugate (ADC): DCDS4501A Anti-CD79b mab conjugated to monomethyl auristatin E (MMAE) via protease-cleavable peptide linker Rapid internalization upon binding Component of B-cell receptor restricted to mature B-cells except plasma cells Expressed by nearly all B-cell hematologic malignancies FL, MZL, MCL, DLBCL, CLL MMAE: microtubule disrupting agent Significant anti-tumor activity in mouse xenograft models of human CD79b+ NHL Tumor volume mm Granta MCL RTX CHOP R-CHOP 2 & 5 mg/kg Anti-CD79bvcE Palanca-Wessels et al, ICML 2013, Abstr. 40
13 Patient Baseline Characteristics Demographics (N=47 patients) All Patients, n (%) Histology Patients, n (%) Age in years, median (range) 64 (20-85) Sex Female Male ECOG status No. systemic therapies, median (range) (36%) 30 (64%) 11 (23%) 26 (55%) 10 (21%) 4 (1-12) 1 (2%) 6 (13%) 40 (85%) Diffuse large B-cell lymphoma 21 (45%) Follicular lymphoma 17 (36%) Mantle cell lymphoma 4 (9%) Marginal zone lymphoma 3 (6%) Small lymphocytic lymphoma 1 (2%) Transformed follicular lymphoma 1 (2%) Prior rituximab therapy 45 (96%) Autologous stem cell transplant therapy 14 (29%)
14 Treatment Emergent Adverse Events * Per investigator assessment
15 Investigator-Assessed Best Responses in patients with at least 1 dose Best Response Efficacy-Evaluable Patients, 1.8 mg/kg (n=17) Objective response b 8 (47%) Histology MCL FL DLBCL Transformed FL Stable disease 3 (18%) Progressive disease 6 (35%) Lugano Update on inhl (n=21) Antibody only (n=12) 7 (58%) Antibody plus rituximab (n=9) 7 (78%) Palanca-Wessels et al, ICML 2013, Abstr. 40
16 Pathway inhibitors 18
17 Targeting the B-Cell-Receptor Pathway Idelalisib GS-9973 Ibrutinib, Ino145 Wiestner, JCO, Doi: /JCO
18 The class of PI3K inhibitors: Idelalisib 20
19 Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-hodgkin lymphoma (inhl). Trial Outline Phase I MTD Dose mg QD/BID NCT Patients with rel indolent Idelasisb until PD mg Patients (n=64) Side effects efficacy Histology 38 FL 11 SLL 9 LPL/WM 6 MZL Patient characteristics Median Age: 64 Median pre Tx: 4 Refractory: 58% AE Grade total/>2 Diarrhea: 36/8% Fatigue: 36/3% Pneumonia: 17/16% AE disc. rate: 12.5% Responses ORR: Median DOR: Median PFS: FL 45% WM 56% MZL 33% All doses / > 100mg BID 48% (1CR)/67% 18.4 m/15.4 m 7.6m /16.6m Kahl et al, ICML 2013, Abstr
20 Interim results of phase II study of idelalisib in inhl refractory to Rituximab and an alkylating agent Trial Outline Phase II MTD 150 mg/bid Patients with rel indolent R-refrac, Alkyl. Ref. Idelasisb 150 BID until PD Patients (n=125) Side effects efficacy Histology 72 FL 28 SLL 10 LPL/WM 15 MZL Patient characteristics Median Age: 64 Median pre Tx: 4 refr to >1 treat: 79% med time since last tx: 4.2m AE Grade total/>2 Diarrhea: 37/10% Fatigue: 28/2% Cough: 26/0% Dyspnoe: 17/3% AST Elev /26% Pneumonia: 17/16% AE disc. rate: 16% Responses ORR: 50.4% CR: 4% PR: 46% SD: 40% FL 49% SLL 64% WM 30% MZL 47% PFS 11.4 m DOR 11.9m Salles et al, ICML 2013, Abstr
21 Interim results of phase II study of idelalisib in inhl refractory to Rituximab and an alkylating agent 23
22 Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with r/r lymphoma IPI-145: oral inhibitor of the PI3KEδ and PI3K-γ isoforms ongoing Phase 1 study 65 pts, 31 with lymphoma, 18 inhl neutropenia and increased ALT were the most common Grade 3 TRAEs MTD 75mg TRAE Pneumonitis, PCP-Pneumonie Median cycle number 4, 48% on treatment Among evaluable pts with lymphoma (n=27), early clinical activity was observed in T-cell (n=6, 1 CR, 1 PR, 1 SD) and aggressive/indolent B-cell (n=21, 2 CR, 9 PR, 5 SD) Kahl et al, ICML 2013, Abstr
23 Perspective: Chemo-free-multi-combinations of novel agents ALLIANCE (Abstract 563) Patients with relapsed FL, Design R2 Plus Idelalisib 25
24 BTK-inhibition - Ibrutinib O N H 2 N N N N N O Fowler et al. ASH 2010 Abst. Honigberg, PNAS, 2010, 26
25 BTK-inhibition in relapsed Lymphoma Advani et al, JCO 2012 DOI: /JCO
26 Waldenström s Macroglobulinemia Treon, NEJM,
27 A prospective, multicentre phase II study of the BTK Inhibitor Inbrutinib in patients with relapsed and refractory Waldenstrom's Macroglobulinemia Trial Outline Relapsed WM, at least 1 treatement Ibrutinib 420mg until progression (26 cycles) Patients Characteristics All 35 refractory 12 Median Age: 63 Median pre Tx: 2 Safety Side effects Grade 3/4 Thrombopenia 15.6% Neutropenia 9.3% Efficacy Responses (32pat) ORR (IWMWS) 81% VGPR 9,3% PR 47% MR weeks on study 94% Treon et al, ICML 2013, Abst
28 Perspective: Ibrutinib in inhl: DAWN Ibrutinib in r/r FL (Abstract 556) Patients with relapsed AND refr inhl, at least 2 lines N=110 I until PD 30
29 Perspective: new targets: SYK Inhibition GS-9973 Phase I, healthy, n=120 Nausea, consipation, headache Grade 3: AST in 3, Grade 4 in 1 Garde 3 creatinin, amylase Abstract 286 Dose finding trial Abstract 548 GS-9973 single agent phase II CLL, inhl, MCL, DLBCL Abstract 551 GS-9973 combination with idelalisib phase II CLL, inhl, MCL, DLBCL Ramanathan et al, ICML 2013, Abstr
30 Bcl-2-inhibition Davids and Letai, Cancer Cell,
31 Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory NHL Trial Outline Phase I NHL mg Dose NCT Single dose 6 d rest Continous dosing Patients Side effects Efficacy Histology All 31 DLBCL 7 MCL 8 FL 7 MW 3 Patient characteristics Median Age: 68 Median pre Tx: 3 AE Grade > 15% Nausea 36% Diarrhea 36% Nausea 16% Vomiting 16% Fatigue 16% Pyrexia: 16% Responses (ORR/CR) 29 ev ORR: 55% DLBCL 3/7 MCL 8/8 WM 3/3 FL 2/7 Davids et al, ICML 2013, Abst
32 Best Percent Change from Baseline in Nodal Size by CT Scan N = 29 evaluable (at minimum, 6 week assessment) Median Time to 50% Reduction = 43 days (range 36 to 113) 34
33 Chemotherapy combination 35
34 Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-hodgkin lymphoma (inhl): Updated results from a phase I study Trial Outline Phase I combo Dose 100/150mg BID NCT Idelalisib 100/150 Rituximab 375mg/m² (6x) Idelalisib 100/150 Bendamustin 90mg/m² (6x) I plus R (6x) plus B (6x) Resp I Patients Side effects Efficacy Histology 78 ind Patient characteristics Median Age: 62 Median pre Tx: 3 Refractory: 41% AE Grade All/ >2 Pyrexia: 56/4% Fatigue: 45/4% Rash: 40/8% Cough 37/0% Diarrhea 36/8% Pneumonia: 17/1% Responses (ORR/CR) ORR all: 71/28% ORR IR: 77/20% ORR IB: 85/29% ORR IBR: 79/43% 20mo PFS: 66% 20mo PFS-R: 73% Leonhard et al, ICML 2013, Abstr
35 BeRT-Schedule Overall 4 cycles planned no mandatory maintenance
36 Dose escalation and treatment completion Phase I completed Defined dosage for Temsriolimus 50mg Entire Treatment completed : 11 patient Average cycle number: 3.47 Response in FL patients 4/4 Phase II ongoing now 16 patients in phase II recruited 38
37 Evolution continues Dep. of Hematology / Oncology / Pneumology
38 Active phase III trial(s) in relapsed inhl R +/- Idelalisib (Abstract 554) Patients with relapsed but not refr inhl, N=350, 2:1 Rando, placebo controlled R R8 plus I until PD R8 plus P until PD BR +/- Idelalisib Patients with relapsed but not refr inhl, N=450, 2:1 Rando, placebo controlled R RB x 6 plus I until PD RB x 6 plus P until PD 40
39 Summary For patients at risk novel drugs are under way moab B-cell-receptor pathway inhibitors Antiapoptotic drugs Value of these drugs in the overall treatment of relapsed indolent lymphoma remains to be determined Combination trials under way Single agent comparisons missing 41
Treatment Nodal Marginal Zone Lymphoma
Workshop : Indolent lymphomas Treatment Nodal Marginal Zone Lymphoma Catherine Thieblemont Hôpital Saint-Louis, Paris - France Bologna 16th, 2017 Ø No standardized treatment Ø Similarly treated as FL Treatment
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationFollicular Lymphoma New Agents. Idelalisib
Indolent Lymphoma Workshop Bologna 2017 Follicular Lymphoma New Agents Idelalisib Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Disclosures of Sven de Vos Company name Research support
More informationB Kahl 1, M Hamadani 2, P Caimi 3, E Reid 4, K Havenith 5, S He 6, JM Feingold 6, O O Connor 7
First Clinical Results of ADCT-42, a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate (ADC), in Relapsed/Refractory B-cell Lineage Non-Hodgkin Lymphoma B Kahl 1, M Hamadani 2, P Caimi 3, E Reid
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationVENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth
VENETOCLAX (ABT 199) Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth ABT-199 Venetoclax ABT-199 is a selective, potent, orally
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationConstan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia
Constan'ne S Tam Victorian Comprehensive Cancer Center Melbourne, Australia BGB-3111: Kinase Selec.vity Rela.ve to Ibru.nib Equipotent against BTK compared to ibru.nib Higher selec.vity vs EGFR, ITK, JAK3,
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationTolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced CLL and NHL
Tolerability and activity of chemo-free triplet combination of umbralisib (TGR-1202), ublituximab, and ibrutinib in patients with advanced and NHL Loretta Nastoupil, MD 1, Matthew A. Lunning, DO 2, Julie
More informationMantle Cell Lymphoma. A schizophrenic disease
23 maggio, 2018 Mantle Cell Lymphoma A schizophrenic disease Patients relapsed after Auto transplant EBMT registry 2000-2009 (n=360) 19 months OS 24 months OS Dietrich S, Ann Oncol 2014 Patients receiving
More informationBcl-2 inhibition in NHL. Jonathan W. Friedberg M.D., M.M.Sc.
Bcl-2 inhibition in NHL Jonathan W. Friedberg M.D., M.M.Sc. BCL-2, BH3 and apoptosis: Rational therapeutic targets in NHL Antiapoptotic proteins, prevent activation of Bax and Bak, thus inhibiting apoptosis.
More information*Jagiellonian University, Kraków, Poland
Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin s Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Wojciech Jurczak, *
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationNew agents for recurrent FL
Lymphoma and Myeloma 2015 Meeting New agents for recurrent FL Sven de Vos, MD, PhD Director, UCLA Lymphoma Program Los Angeles, CA Indolent Lymphoma Percent Survival Year 60 mos 120 mos 1944-54 29.3 17.2
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationFirenze, settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo
Firenze, 22-23 settembre 2017 Novità dall EHA LINFOMI Umberto Vitolo Hematology University Hospital Città della Salute e della Scienza Torino, Italy Disclosures Umberto Vitolo Research Support/P.I. Employee
More informationBTK Inhibitors and BCL2 Antagonists
BTK Inhibitors and BCL2 Antagonists Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia and Indolent Lymphoma, Peter MacCallum Cancer
More informationSecond Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111)
Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia
More informationCLL: Future Therapies. Dr. Anca Prica
CLL: Future Therapies Dr. Anca Prica Treatment Options: Improved by Decade 1960 1970 1980 1990 2000 2017 5% CR 5% CR Chemo Alkylator chlorambucil or cyclophosphamide 25% CR Chemo Purine analogues Fludarabine
More informationWhat from the basket of BTK and PI3K inhibitors?
What from the basket of BTK and PI3K inhibitors? Steven M. Horwitz M.D. Associate Attending Lymphoma Service Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationBendamustine: A Transversal * Chemotherapy Agent
Bendamustine: A Transversal * Chemotherapy Agent Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA *Def Cutting across two lines, intersecting
More informationBTKi in MCL. Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK
BTKi in MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK 2 Table of Various Treatment for R/R MCL Treatment Study or
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationClinical Advances in Lymphoma
Conflicts of Interest Clinical Advances in Lymphoma Alex F. Herrera, MD Assistant t Professor Department of Hematology and HCT City of Hope BMS research funding (institutional), consultancy Genentech research
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationLymphoma- Med A-new drugs and treatments
Lymphoma- Med A-new drugs and treatments Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Disclosures: Roche, Gilead Silvia Montoto Lisbon, 19/03/2018 #EBMT18 www.ebmt.or Outline Lymphoma- what is
More informationDuvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia
Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, is Clinically Active in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia Susan M. O Brien 1, Manish R. Patel 2,3, Brad Kahl 4, Steven Horwitz 5,
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationNuove opportunità di cura. Stefano Sacchi, Modena
Nuove opportunità di cura Stefano Sacchi, Modena Antiangiogenesis therapies The goal is to target the blood supply that feeds tumors. Vorinostat (suberoylanilide hydroxamic acid - SAHA) TOPIC SEARCH:
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationHighlights in chronic lymphocytic leukemia
Congress Highlights CLL Highlights in chronic lymphocytic leukemia A. Janssens, MD, PhD 1 As new data on indolent non-hodgkin lymphoma (inhl) were not that compelling, only highlights on chronic lymphocytic
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationMANTLE CELL LYMPHOMA MTOR-INHIBITION
MANTLE CELL LYMPHOMA MTOR-INHIBITION Rome, 23. March 2017 Prof. Dr. med. Georg Heß III. Med. Klinik Universitäres Centrum für Tumorerkrankungen Universitätsmedizin der Johannes Gutenberg-Universität Mainz
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationVenetoclax in MCL. Prof. Le Gouill Nantes Medical University, France
Venetoclax in MCL Prof. Le Gouill Nantes Medical University, France Evasion of Apoptosis, or Cell Death, is 1. Resisting Cell Death 2. Sustained angiogenesis for growth and survival (primarily solid tumors)
More informationOptions in Mantle Cell Lymphoma Therapy
Options in Mantle Cell Lymphoma Therapy Carlo Visco, MD Dept of Cell Therapy and Hematology San Bortolo Hospital, Vicenza, taly My Disclosures: ADVSOR OR ADVSORY BOARDS: Lundbeck Canada nc, Celgene Europe,
More informationEmerging targeted therapies for follicular lymphoma A future without chemotherapy
Emerging targeted therapies for follicular lymphoma A future without chemotherapy Pier Luigi Zinzani Institute of Hematology L. e A. Seràgnoli University of Bologna FOLLICULAR LYMPHOMA: GENERAL ASPECTS
More informationKamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA
Kamakshi V Rao, PharmD, BCOP, FASHP University of North Carolina Medical Center UPDATE IN REFRACTORY HODGKIN LYMPHOMA Objectives Describe the current standard approach for patients with relapsed/refractory
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationState of the Art Treatment for Relapsed Mantle Cell Lymphoma
Winship Cancer Institute of Emory University State of the Art Treatment for Relapsed Mantle Cell Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor, BMT Program Emory University- Winship Cancer Institute
More informationNovita da EHA 2016 Copenhagen Linfomi
Firenze, 16th September 2016 Marco Ladetto MD, Az Osp Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy EU Novita da EHA 2016 Copenhagen Linfomi THREE QUESTIONS TO ADDRESS: 1. Is ASCT still the
More informationOSCO/OU ASH-SABC Review. Lymphoma Update. Mohamad Cherry, MD
OSCO/OU ASH-SABC Review Lymphoma Update Mohamad Cherry, MD Outline Diffuse Large B Cell Lymphoma Double Hit Lymphoma Follicular and Indolent B Cell Lymphomas Mantle Cell Lymphoma T Cell Lymphoma Hodgkin
More informationExpert Perspective on ASH 2014: Lymphoma
Expert Perspective on ASH 2014: Lymphoma Myron S. Czuczman, MD Abstract The 2014 Annual Meeting and Exposition of the American Society of Hematology included many updates of previously presented studies,
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More information2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용
2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationDELIVERING NEXT-GENERATION RADIO-IMMUNOTHERAPIES FOR LYMPHOMA PATIENTS
DELIVERING NEXT-GENERATION RADIO-IMMUNOTHERAPIES FOR LYMPHOMA PATIENTS DNB SME CONFERENCE 4 TH APRIL, 2019 EDUARDO BRAVO, CEO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationNew developments in the treatment of FL. Massimo Federico University of Modena and Reggio Emilia Italy
New developments in the treatment of FL Massimo Federico University of Modena and Reggio Emilia Italy Common Questions Asked by The Patient I would like to know what is the best therapeutic option and
More informationBrentuximab Vedotin in Lymphomas
New Drugs In Hematology Brentuximab Vedotin in Lymphomas Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center Monday, May 9, 2016 9:15-9:45 a.m U.S. Cancer Statistics 2016 300.000
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationClinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia
Clinical Trial News on the Treatment of Waldenstrom s Macroglobulinemia Edward Libby M.D. Associate Professor, University of Washington Department of Medicine, Division of Medical Oncology Fred Hutchinson
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationIdelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL
Idelalisib treatment is associated with improved cytopenias in patients with relapsed/refractory inhl and CLL Susan M O Brien, Andrew J Davies, Ian W Flinn, Ajay K Gopal, Thomas J Kipps, Gilles A Salles,
More informationIndolent Lymphomas and Hodgkin Lymphoma: Achieving Curability
Indolent Lymphomas and Hodgkin Lymphoma: Achieving Curability Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C. Di$clo$ure$ Consulting & advisory
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationWe Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT
We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT Danielle M. Brander, MD Duke University Division of Hematologic Malignancies & Cell Therapy CLL & Indolent
More informationDYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA Presented at 14-ICML, 14 June 2017, Lugano Switzerland Authors
More informationNASDAQ: TGTX. J.P. Morgan Healthcare Conference January 2017
NASDAQ: TGTX J.P. Morgan Healthcare Conference January 2017 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationManagement of high-risk diffuse large B cell lymphoma: case presentation
Management of high-risk diffuse large B cell lymphoma: case presentation Daniel J. Landsburg, MD Assistant Professor of Clinical Medicine Perelman School of Medicine University of Pennsylvania January
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationDisclosures of XXXXX
Disclosures of XXXXX Company name Research support Employee Consultant Stockholder Speakers bureau Advisory board Other Abbvie X X Genentech X X Gilead X Bayer X X Incyte X Samus Therapeutics X BCL-2 Inhibitors
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationThe Map of Current Treatment Options for Waldenström Macroglobulinemia
The Map of Current Treatment Options for Waldenström Macroglobulinemia Craig Reeder Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida DISCLOSURES Relevant Financial Relationship(s)
More informationImmune checkpoint inhibitors in lymphoma. Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust
Immune checkpoint inhibitors in lymphoma Catherine Hildyard Haematology Senior Registrar Oxford University Hospitals NHS Foundation Trust Aims How immune checkpoint inhibitors work Success of immune checkpoint
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationUBS European Conference 2013
UBS European Conference 2013 Tuesday, 12 November 2013 Karl Mahler, Head of Investor Relations Stefan Frings, Oncology/Immunology Therapeutic Area Head,Roche Partnering Group: Continued strong sales growth
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationBACKGROUND AND RATIONALE
SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More information